In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Tiegang ^a   He, Jiuming ^a   Mao, Xinxin ^b   Bi, Ying ^c   Luo, Zhigang ^a   Guo, Chengan ^c   Tang, Fei ^c   Xu, Xin ^d   Wang, Xiaohao ^c   Wang, Mingrong ^d   Chen, Jie ^b   Abliz, Zeper ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c TSINGHUA UNIVERSITY   (China)

^d CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MASS SPECTROMETRY; METABOLISM; METABOLOME; METABOLOMICS; PROCEDURES; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; MICROSCOPY, FLUORESCENCE; SENSITIVITY AND SPECIFICITY;

EID: 84942777088     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14089     Document Type: Article

References (53)

1. Naumova, A. V, et al. Clinical imaging in regenerative medicine. Nat. Biotechnol. 32, 804-818 (2014).
2. Dubbink, H. J, et al. Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol. Oncol. 8, 830-839 (2014).
3. Harris, T. J. R., & McCormick, F. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 7, 251-265 (2010).
4. Tan D., & Lynch, H. T. Principles of molecular diagnostics and personalized cancer medicine. Lippincott Williams & Wilkins, 2012).
5. Wootton, R. Telehealth in the developing world. (IDRC, 2009).
6. Mahe, E, et al. Intraoperative pathology consultation: error, cause and impact. Can. J. Surg. 56, E13 (2013).
7. Patti, G. J., Yanes, O., & Siuzdak, G. Innovation: metabolomics: the apogee of the omics trilogy. Nat. Rev. Mol. Cell Bio. 13, 263-269 (2012).
8. Burke, M. F., Dunbar, R. L., & Rader, D. J. Could exercise metabolomics pave the way for gymnomimetics? Sci. Transl. Med. 2, 41ps35-41ps35 (2010).
9. Langenberg, C., & Savage, D. B. An amino acid profile to predict diabetes? Nat. Med. 17, 418 (2011).
10. Green, D. R., Galluzzi, L., & Kroemer, G. Cell biology. Metabolic control of cell death. Science 345, 1250256 (2014).
11. Auro, K, et al. A metabolic view on menopause and ageing. Nat. Commun. 5, 4708 (2014).
12. Wang, T. J, et al. Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448-453 (2011).
13. Baker, M. Metabolomics: from small molecules to big ideas. Nat. Methods 8, 117-121 (2011).
14. Mishra, P., & Ambs, S. Metabolic signatures of human breast cancer. Mol., & Cell Oncol. e992217(1-10) (2014).
15. Nelson, S. J, et al. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci. Transl. Med. 5, 198ra108 (2013).
16. Giesen, C, et al. Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 11, 417-422 (2014).
17. Perkel, J. M. Mass spec imaging from bench to bedside. Science 340, 1119-1121 (2013).
18. Rimm, D. L. Next-gen immunohistochemistry. Nat. Methods 11, 381-383 (2014).
19. McDonnell, L. A., & Heeren, R. Imaging mass spectrometry. Mass Spectrom.Rev. 26, 606-643 (2007).
20. Schwamborn, K., & Caprioli, R. M. Molecular imaging by mass spectrometry-looking beyond classical histology. Nat. Rev. Cancer 10, 639-646 (2010).
21. Morita, Y, et al. Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J. Hepatol. 59, 292-299 (2013).
22. Eberlin, L. S, et al. Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Rese. 72, 645-654 (2012).
23. Eberlin, L. S, et al. Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc. Natl. Acad. Sci. USA 110, 1611-1616 (2013).
24. Jemal, A, et al. Global cancer statistics. CA: a cancer journal for clinicians. 61(2), 69-90, (2011).
25. Groseclose, M. R, et al. High-Throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 8, 3715-3724(2008).
26. Groseclose, M. R. High-Throughput analysis of tissue microarrays of disease: combining in situ proteomics with MALDI imaging mass spectrometry, PhD thesis, Vanderbilt University (2009).
27. Guo, S, et al. Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci. Rep. 4, 5959 (2014).
28. He, J, et al. Air flow assisted ionization for remote sampling of ambient mass spectrometry and its application. Rapid Commun. Mass Spectrom. 25, 843-850 (2011).
29. Luo, Z, et al. Air flow-Assisted ionization imaging mass spectrometry method for easy whole-body molecular imaging under ambient conditions. Anal. Chem. 85, 2977-2982 (2013).
30. He, J, et al. Ambient mass spectrometry imaging metabolomics method provides novel insights into action mechanism of drug candidate. Anal. Chem. 87, 5372-5379 (2015).
31. Eberlin, L. S., Ferreira, C. R., Dill, A. L., Ifa, D. R., & Cooks, R. G. Desorption electrospray ionization mass spectrometry for lipid characterization and biological tissue imaging. Biochim. Biophys. Acta 1811, 946-960 (2011).
32. Bylesjo, M, et al. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. J. Chemometr. 20, 341-351 (2006).
33. Xu, J, et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. Mol. Cell. proteomics 12, 1306-1318 (2013).
34. Shen, G, et al. Time-course changes in potential biomarkers detected using a metabonomic approach in Walker 256 tumorbearing rats. J. Proteome Res. 10, 1953-1961 (2011).
35. Chen, Y, et al. Assessment of data pre-processing methods for LC-MS/MS-based metabolomics of uterine cervix cancer. The Analyst 138, 2669-2677 (2013).
36. Miura, D., Fujimura, Y., & Wariishi, H. In situ metabolomic mass spectrometry imaging: recent advances and difficulties. J. Proteomics 75, 5052-5060 (2012).
37. Zhou, W., Liotta, L. A., & Petricoin, E. F. Cancer metabolism: what we can learn from proteomic analysis by mass sapectrometry. Cancer Genomics-Proteom. 9, 373-381 (2012).
38. Ruiz-Cabello, J., & Cohen, J. S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 5, 226-233 (1992).
39. Munoz-Pinedo, C., El Mjiyad, N., & Ricci, J. E. Cancer metabolism: current perspectives and future directions. Cell death Dis. 3, e248 (2012).
40. Glunde, K., Bhujwalla, Z. M., & Ronen, S. M. Choline metabolism in malignant transformation. Nat. Rev. Cancer 11, 835-848 (2011).
41. Liu, W, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc. Natl. Acad. Sci. USA 109, 8983-8988 (2012).
42. Moestue, S., Sitter, B., Bathen, T. F., Tessem, M. B., & Gribbestad, I. S. HR MAS MR spectroscopy in metabolic characterization of cancer. Curr. Top. Med. Chem. 11, 2-26 (2011).
43. Hori, S, et al. A metabolomic approach to lung cancer. Lung cancer 74 284-292 2011).
44. Katz-Brull, R, et al. Metabolic markers of breast cancer enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 62(7), 1966-1970(2002).
45. Yang, Q, et al. Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J. Sep. Sci. 33, 1495-1503 (2010).
46. Khalil, R M., El-Bahrawy, H., El-Ashmawy, N. E., & Darwish, H. l-carnitine decreases Her-2/neu in breast cancer patients treated with tamoxifen. IOSR-JPBS 5 91-98 2013).
47. Peluso, G, et al. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J. Cell. Physiol. 182, 339-350 (2000).
48. Eberlin, L. S, et al. Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal. Chem. 82, 3430-3434 (2010).
49. Dill, A. L, et al. Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry. Anal. Bioanal. Chem. 398, 2969-2978 (2010).
50. Wu, C, et al. Molecular imaging of adrenal gland by desorption electrospray ionization mass spectrometry. The Analyst 135, 28-32 (2010).
51. Zhu, Z, et al. Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database. Nat. Protoc. 8, 451-460 (2013).
52. Kirwan, J. A, et al. Direct infusion mass spectrometry metabolomics dataset: a benchmark for data processing and quality control. Scientific Data 1, doi: 10.1038/sdata.2014.12 (2014).
53. Want, E. J, et al. Global metabolic profiling of animal and human tissues via UPLC-MS. Nat. Protoc. 8, 17-32 (2013).